(NASDAQ: NRXP) Nrx Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 107.7%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 26.15%.
Nrx Pharmaceuticals's revenue in 2025 is $0.On average, 6 Wall Street analysts forecast NRXP's revenue for 2025 to be $524,095,933, with the lowest NRXP revenue forecast at $337,942,071, and the highest NRXP revenue forecast at $724,161,580. On average, 6 Wall Street analysts forecast NRXP's revenue for 2026 to be $2,594,764,539, with the lowest NRXP revenue forecast at $822,647,555, and the highest NRXP revenue forecast at $4,994,645,867.
In 2027, NRXP is forecast to generate $10,719,364,837 in revenue, with the lowest revenue forecast at $9,889,189,943 and the highest revenue forecast at $11,473,675,185.